BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsClinical readout

– Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking Featured Science Session.05 on Saturday, November 7 – – Pooled SHASTA -3/4 Analysis of Triglyceride

Related news

ARWRArrowhead Pharmaceuticals2026-08-24 11:30 EST

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

ARWRArrowhead Pharmaceuticals2026-09-29 11:30 EST

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

PHVSPharvaris2026-10-29 10:50 EST

Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

BIIBBiogen2026-09-17 20:15 EST

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

BIIBBiogen2026-09-03 23:30 EST

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

MNPRMonopar2026-11-02 13:00 EST

Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data

TARAProtara Therapeutics2026-10-15 12:00 EST

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

RHHBYRoche Holdings AG2026-10-21 12:00 EST

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

PHVSPharvaris2026-10-08 22:35 EST

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

View all latest news

Arrowhead Pharmaceuticals

RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in...

Recent company news

ARWRArrowhead Pharmaceuticals2026-11-07 21:15 EST

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

ARWRArrowhead Pharmaceuticals2026-11-04 12:30 EST

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

ARWRArrowhead Pharmaceuticals2026-11-03 21:00 EST

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

ARWRArrowhead Pharmaceuticals2026-11-02 12:30 EST

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

ARWRArrowhead Pharmaceuticals2026-10-27 15:36 EST

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

Stock data

Close
57.46 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States